Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc.ADRX · Entity 183937 | Director · President and CEO · 10% owner | September 24, 2026 | September 28, 2026 |
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Snr. VP, Chem and Non-Clin Dev | January 14, 2019 | January 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADARx Pharmaceuticals, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-09-23 | Direct | 1,024,152 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 1,024,152 · Balance 1,024,152 F1: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 14, 2019 · Filed January 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,700 |
Reported balance
After 2019-01-14 transaction · row 1
1 source rowRow 1 · 2019-01-14 · Sale · Disposed 40,500 · Balance 201,700 F1: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.
F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC | ADARx Pharmaceuticals, Inc. ADRX · Entity 183937 | GrantEmployee Stock Option (right to buy) · Derivative | 1,024,152 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001729510-26-000006 · form4-09282026_040901.xml · derivative · entry 1 Li Zhen · CIK 0001729510 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,152 Underlying: Common Stock · 1,024,152 shares Expires 2036-09-23 F1 · derivative.exercise_date: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:24 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 40,500 | $14.34 | $580,770.00 |
DisclosureSEC source: 0001209191-19-004005 · doc4.xml · nonDerivative · entry 1 Li Zhen · CIK 0001729510 · Snr. VP, Chem and Non-Clin Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,700 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001522 · doc4.xml · nonDerivative · entry 1 Li Zhen · CIK 0001729510 · Snr. VP, Chem and Non-Clin Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,200 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.